logo
Plus   Neg
Share
Email

Micro Focus Suspends Final Dividend - Quick Facts

Micro Focus International plc. (MCRO.L) said that its board is no longer recommending a final dividend for the year ended 31 October 2019 and therefore it plans to withdraw resolution relating to the approval of a proposed final dividend of 58.33 cents per ordinary share at its forthcoming Annual General Meeting. The move is due to the current increased macro uncertainty, which has been impacted by the global spread of COVID-19.

The company said it will consider paying a second interim dividend in respect of the year ended 31 October 2019 once there is some visibility on the effects of the COVID-19 on the company's business.

The company's Annual General Meeting will be held on 25 March 2020.

In view of the ongoing COVID-19 pandemic, Micro Focus is asking shareholders to appoint the Chairman as their proxy -- either electronically or by post-- with their voting instructions rather than attend the AGM in person.

The deadline for voting is on 23 March 2020 for shareholders and on 18 March 2020 for ADR shareholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process. The U.S. Food and Drug Administration announced the approval of Trevena Inc.'s Olinvyk (oliceridine), a new opioid for intravenous use in hospitals or other controlled clinical settings. Olinvyk is an opioid agonist to manage moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
RELATED NEWS
Follow RTT